The Wisconsin Innovation Index is your guide to Wisconsin’s entrepreneurial assets. It maps our statewide corporate WIN member network of entrepreneurs, investors, incubators, accelerators, academic resources, companies, professional service firms and government resources tied to the growth of Wisconsin’s high-tech economy. CLICK HERE to view a map of these innovators.
Join the Innovation Network to be listed on the Innovation Index.
Support for this project was made possible by American Family Insurance.
No Image Available
BiographyNo Image Available
Arrowhead Research Corporation develops novel drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.